Trial · NCT02572791

Staph Household Intervention for Eradication (SHINE)

NCT02572791, Phase 4, Completed, Washington University School of Medicine; results first posted 2026-02-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Staph Household Intervention for Eradication (SHINE). Trials, record NCT02572791. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02572791

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Staph Household Intervention for Eradication (SHINE)
NCT number: NCT02572791
Status: Completed
Phases: Phase 4
Enrollment: 835 participants, actual
Lead sponsor: Washington University School of Medicine
Conditions: Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus, MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Chlorhexidine, Mupirocin, Household cleaning
First posted: 2015-10-09
Last updated: 2026-02-24
Results first posted: 2026-02-24
Limitations and caveats: Due to the COVID-19 pandemic, we stopped early at 196, rather than 207 households.

Source ClinicalTrials.gov

Registered outcomes21

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Households With at Least One Skin and Soft Tissue Infection	3 months after randomization	Number of households with at least one SSTI between the Integrated Decolonization Group and the combined Personal Periodic Decolonization and Environmental Decontamination Groups.
Secondary	Prevalence of MRSA Colonization in Participants	Baseline sampling	Describe baseline prevalence of MRSA colonization in participants
Secondary	Prevalence of MRSA Colonization in Participants	9 months	Describe longitudinal MRSA colonization prevalence in participants
Secondary	Confirmed S. Aureus Infection	9 months	We will compare the development of a confirmed S. aureus infection between participants in the 3 groups over 9 months at the household and individual level.
Secondary	Incidence of SSTI	1 month	We will compare the number of households in which at least one household member develops SSTI 1 month after randomization between the Integrated Decolonization Group and the combined Personal Periodic Decolonization and Environmental Decontamination Groups.
Secondary	Incidence of SSTI	6 months	We will compare the incidence of households in which at least one household member experiences an SSTI at the household level 6 months after randomization between the Integrated Decolonization Group and the combined Personal Periodic Decolonization and Environmental Decontamination Groups.
Secondary	Incidence of SSTI	9 months	We will compare the number of households in which at least one household member develops SSTI 9 months after randomization between the Integrated Decolonization Group and the combined Personal Periodic Decolonization and Environmental Decontamination Groups.
Secondary	Mupirocin Resistance	9 months	Measure the prevalence of mupirocin resistance in S. aureus strains recovered at serial samplings over the study period of 9 months.
Secondary	Number of Patients With Adverse Events Due to Study Intervention	3 months	We will describe the number of participants with adverse events due to study intervention (e.g., rhinorrhea, rash, dry skin) and compare between the three groups.
Secondary	Number of Participants Adhering to Study Intervention Procedures	3 months	We will describe the number of participants completing chlorhexidine baths, mupirocin applications, and household hygiene measures.

1 to 10 of 21Source ClinicalTrials.gov

See all 21 registered outcomes

Outcomes21

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Households With at Least One Skin and Soft Tissue Infection	3 months after randomization	We evaluated the primary outcome at the level of the household.	Households	COUNT_OF_UNITS
SECONDARY	Prevalence of MRSA Colonization in Participants	Baseline sampling	Participants colonized with MRSA at the baseline sampling	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Prevalence of MRSA Colonization in Participants	9 months	Participants cultured for MRSA detection at the 9 month study visit	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Confirmed S. Aureus Infection	9 months	Participants reporting SSTI throughout the longitudinal study	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Incidence of SSTI	1 month	Household level	Households	COUNT_OF_UNITS
SECONDARY	Incidence of SSTI	6 months	Households	Households	COUNT_OF_UNITS
SECONDARY	Incidence of SSTI	9 months	Households	Households	COUNT_OF_UNITS
SECONDARY	Mupirocin Resistance	9 months	Participants sampled at 9 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Patients With Adverse Events Due to Study Intervention	3 months	Participants providing AE data	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Adhering to Study Intervention Procedures	3 months	Participants completing the 3 month intervention	Participants	COUNT_OF_PARTICIPANTS

1 to 10 of 21Source ClinicalTrials.gov

See all 21 outcomes

Results by group63

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Households With at Least One Skin and Soft Tissue Infection	Periodic Personal Decolonization	21	Households
Number of Households With at Least One Skin and Soft Tissue Infection	Integrated Personal/Household Hygiene	21	Households
Number of Households With at Least One Skin and Soft Tissue Infection	Household Environmental Hygiene	22	Households
Prevalence of MRSA Colonization in Participants	Periodic Personal Decolonization	39	Participants
Prevalence of MRSA Colonization in Participants	Integrated Personal/Household Hygiene	61	Participants
Prevalence of MRSA Colonization in Participants	Household Environmental Hygiene	60	Participants
Prevalence of MRSA Colonization in Participants	Periodic Personal Decolonization	12	Participants
Prevalence of MRSA Colonization in Participants	Integrated Personal/Household Hygiene	22	Participants
Prevalence of MRSA Colonization in Participants	Household Environmental Hygiene	24	Participants
Confirmed S. Aureus Infection	Periodic Personal Decolonization	84	Participants

1 to 10 of 63Source ClinicalTrials.gov

See all 63 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants	Units counted
Intervention Period: Months 0-3	STARTED	Periodic Personal Decolonization	273	65
Intervention Period: Months 0-3	STARTED	Household Environmental Hygiene	270	65
Intervention Period: Months 0-3	STARTED	Integrated Personal/Household Hygiene	290	66
Intervention Period: Months 0-3	COMPLETED	Periodic Personal Decolonization	228	57
Intervention Period: Months 0-3	COMPLETED	Household Environmental Hygiene	235	58
Intervention Period: Months 0-3	COMPLETED	Integrated Personal/Household Hygiene	255	59
Intervention Period: Months 0-3	NOT COMPLETED	Periodic Personal Decolonization	45	8
Intervention Period: Months 0-3	NOT COMPLETED	Household Environmental Hygiene	35	7
Intervention Period: Months 0-3	NOT COMPLETED	Integrated Personal/Household Hygiene	35	7
Post-Intervention Period: Months 4-9	STARTED	Periodic Personal Decolonization	229	57

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Adverse Event from Chlorhexidine application	Skin and subcutaneous tissue disorders	Periodic Personal Decolonization	61	274	61
other	Adverse Event from Chlorhexidine application	Skin and subcutaneous tissue disorders	Household Environmental Hygiene	62	269	62
other	Adverse Event from Chlorhexidine application	Skin and subcutaneous tissue disorders	Integrated Personal/Household Hygiene	101	292	101
other	Adverse Event from Mupirocin application	Skin and subcutaneous tissue disorders	Periodic Personal Decolonization	74	274	74
other	Adverse Event from Mupirocin application	Skin and subcutaneous tissue disorders	Household Environmental Hygiene	64	269	64
other	Adverse Event from Mupirocin application	Skin and subcutaneous tissue disorders	Integrated Personal/Household Hygiene	88	292	88

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Periodic Personal Decolonization	0	274
Total, all-cause mortality	Household Environmental Hygiene	0	269
Total, all-cause mortality	Integrated Personal/Household Hygiene	0	292
Total, other adverse events	Periodic Personal Decolonization	111	274
Total, other adverse events	Household Environmental Hygiene	93	269
Total, other adverse events	Integrated Personal/Household Hygiene	137	292
Total, serious adverse events	Periodic Personal Decolonization	0	274
Total, serious adverse events	Household Environmental Hygiene	0	269
Total, serious adverse events	Integrated Personal/Household Hygiene	0	292

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02572791

GET https://conductscience.org/api/trials/v1/NCT02572791/registered?page=2

API reference For AI assistants